Iovance hits two-year high after raising annual revenue forecast

By Reuters News

** Shares of Iovance Biotherapeutics IOVA.O rise 27.5% to $14, their highest level in more than two years

** Co raises FY26 revenue outlook to $410 mln-$420 mln, from a prior forecast of $350 mln-$370 mln

** "Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint," CEO says

** 8 of 10 brokerages rate the stock "buy" or higher and two "hold"; median PT is $11 — data compiled by LSEG

** Including session's move, stock has jumped more than five times in value YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.